

Clinical outcomes in patients with HR+/HER2– early breast cancer by prior systemic treatment: a subgroup analysis of the NATALEE trial

Nicholas McAndrew, Stephen Chia, Fabio Puglisi, Aditya Bardia, Yann Izarzugaza, Christian Schem, Binghe Xu, Fanny Le Du, Priyanka Sharma, Karen Afenjar, Murat Akdere, Juan Pablo Zarate, Yogesh Chattar, Peter A. Fasching

- The proportion of patients with any CT increased as nodal involvement or anatomic stage increased (Supplementary table 1)
 - Percentages of patients receiving neoadjuvant CT or adjuvant CT also varied by nodal status and stage

Supplementary Table 1. Prior CT by Nodal Status or Anatomic Stage

Subgroup, %	NX		N0		N1		N2		N3		Missing	
	RIB + NSAI (n=274)	NSAI alone (n=264)	RIB + NSAI (n=695)	NSAI alone (n=737)	RIB + NSAI (n=1049)	NSAI alone (n=1049)	RIB + NSAI (n = 331)	NSAI alone (n=292)	RIB + NSAI (n=151)	NSAI alone (n=175)	RIB + NSAI (n=49)	NSAI alone (n=35)
Any CT	87.96	88.64	76.69	78.70	91.52	90.09	97.89	97.60	98.01	98.86	87.76	80.00
Any neoadjuvant CT ^a	15.33	19.32	18.71	20.76	57.29	56.34	61.33	61.64	66.89	67.43	16.33	5.71
Any adjuvant CT ^a	73.36	69.70	59.71	59.84	37.37	37.27	38.97	38.36	33.77	37.71	71.43	74.29
No CT	12.04	11.36	23.31	21.30	8.48	9.91	2.11	2.40	1.99	1.14	12.24	20.00
	Stage I		Stage II		Stage III		Missing					
	RIB + NSAI (n=9)	NSAI alone (n=5)	RIB + NSAI (n=1011)	NSAI alone (n=1034)	RIB + NSAI (n=1528)	NSAI alone (n=1512)	RIB + NSAI (n=1)	NSAI alone (n=1)				
Any CT	66.67	60.00	76.06	76.31	96.40	96.03	100.00	100.00				
Any neoadjuvant CT ^a	0	20.00	28.78	28.24	51.96	53.04	0	0				
Any adjuvant CT ^a	66.67	40.00	49.26	49.03	46.99	46.96	100.00	100.00				
No CT	33.33	40.00	23.94	23.69	3.60	3.97	0	0				

^a Includes 129 patients (2.5%) who received both neoadjuvant and adjuvant CT.